SCHEMBL4903273

SCHEMBL4903273

CCOC(=O)N1CCN(CC(=O)Nc2ccc(C)c(Nc3nccc(-c4ccccn4)n3)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
KDM4E B2RXH2 3/20 0.54
LMNA P02545 3/20 0.54
TSHR P16473 1/20 0.54
MAPT P10636 2/20 0.51
USP2 O75604 1/20 0.51
HPGD P15428 1/20 0.51
ALOX15 P16050 1/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51
HSD17B10 Q99714 1/20 0.51
ABL1 P00519 6/20 0.49
SYK P43405 6/20 0.49
BCR P11274 5/20 0.49
KIT P10721 2/20 0.49
ABL2 P42684 2/20 0.49
ABCB1 P08183 3/20 0.49
TDP1 Q9NUW8 1/20 0.47
EGFR P00533 2/20 0.47
PDGFRB P09619 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4903418 0.90 ALDH1A1 (0.59) ALDH1A1KDM4ELMNATSHRMAPT
SCHEMBL4900241 0.89 SYK (0.53) ALDH1A1KDM4ELMNATSHRMAPT
SCHEMBL4892505 0.89 ABL1 (0.57) LMNAABL1SYKBCRKIT
SCHEMBL4893382 0.88 LMNA (0.50) ALDH1A1KDM4ELMNAHSD17B10ABL1
SCHEMBL4901647 0.88 ALDH1A1 (0.54) ALDH1A1KDM4ELMNATSHRABL1
SCHEMBL4897520 0.87 ABL1 (0.67) LMNAABL1SYKBCRKIT
SCHEMBL4896431 0.87 ABL1 (0.52) ABL1SYKBCRKITABL2
SCHEMBL4901214 0.81 PDGFRA (0.64) ABL1BCRKITABL2EGFR
SCHEMBL4905299 0.80 SMN1; SMN2 (0.56) ALDH1A1LMNATSHRABL1SYK
Cyclohexane SCHEMBL5775921 0.78 ABL1 (0.61) ABL1SYKBCRKITABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP ALDH1A1 376/4885KDM4E 2352/4885LMNA 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.